Vidaza 100 mg Powder for suspension for injection
PDF Leaflet Revision Date: 21 October 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adult patients with Myelodysplastic syndromes (MDS) and certain leukemias.
Dosage (summary)
75 mg/mu00b2 daily for 7 days, followed by 21 days rest; minimum 6 cycles.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding; effective contraception required.
Contraindications
- Hypersensitivity to azacitidine
- Malignant hepatic tumors
- Live vaccines
- Children under 18
Common side effects
- Anaemia
- Thrombocytopenia
- Neutropenia
- Nausea
- Vomiting
Counselling Points
- Monitor for signs of bleeding
- Report febrile episodes
- Avoid pregnancy during treatment
Serious warnings
- Haematological toxicity
- Differentiation syndrome
- Renal impairment risks
Important Disclaimer
The Vidaza 100 mg Powder for suspension for injection professional information leaflet below is the property of Key Oncologics and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
